Raphaël Cornu

Raphaël Cornu

Auto-generated profile, based on publicly available information

Raphaël Cornu

PEPITE EA4267, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Toxicology
Verified
Journal Article
Closed access
RCRaphaël Cornu
Raphaël Cornu
ABArnaud Beduneau
Arnaud Beduneau
HMhelene MARTIN
helene MARTIN

11 March 2020 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
RCRaphaël Cornu
Raphaël Cornu
CCClaire Chrétien
Claire Chrétien
YPYann Pellequer
Yann Pellequer
HMHélène Martin
Hélène Martin
ABArnaud Beduneau
Arnaud Beduneau

27 July 2022 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
RCRaphaël Cornu
Raphaël Cornu
ABArnaud Beduneau
Arnaud Beduneau
HMhelene MARTIN
helene MARTIN

30 April 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DPDuy Toan Pham
Duy Toan Pham
NSNuttawut Saelim
Nuttawut Saelim
RCRaphaël Cornu
Raphaël Cornu
ABArnaud Beduneau
Arnaud Beduneau
WTWaree Tiyaboonchai
Waree Tiyaboonchai
Recently, crosslinked fibroin nanoparticles (FNP) using the crosslinker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) or the polymer poly(ethylenimine) (PEI) have been developed and showed potentials as novel drug delivery systems. Thus, this study further investigated the biological properties of these crosslinked FNP by labeling them with fluorescein isothiocyanate (FITC) for in vitro studies. All formulations possessed a mean particle size of approximately 300 nm and a tunable zeta potential (−20 to + 30 mV) dependent on the amount/type of crosslinkers. The FITC-bound FNP showed no significant difference in physical properties compared to the blank FNP. They possessed a binding efficacy of 3.3% w/w, and no FITC was released in sink condition up to 8 h. All formulations were colloidal stable in the sheep whole blood. The degradation rate of these FNP in blood could be controlled depending on their crosslink degree. Moreover, no potential toxicity in erythrocytes, Caco-2, HepG2, and 9L cells was noted for all formulations at particle concentrations of < 1 mg/mL. Finally, all FNP were internalized into the Caco-2 cells after 3 h incubation. The uptake rate of the positively charged particles was significantly higher than the negatively charged ones. In summary, the crosslinked FNP were safe and showed high potentials as versatile systems for biomedical applications.

7 February 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
RCRaphaël Cornu
Raphaël Cornu
NRNathalie Rougier
Nathalie Rougier
YPYann Pellequer
Yann Pellequer
Alf LamprechtAlf Lamprecht
Alf Lamprecht
PHPaul Hamon
Paul Hamon
HMhelene MARTIN
helene MARTIN
Nanomedicines represent a promising approach in the treatment and diagnosis of numerous disorders. The majority of the injected dose of nanoparticles (NPs) is sequestrated in the liver. Despite this hepatic tropism, the interaction of NPs with the detoxification function of the liver remains unclear. The present study consists of evaluating the impact of biodegradable poly(lactide-co-glycolide) (PLGA) and silica NPs on cytochrome P450 (CYP) activities. The effects of NPs were evaluated in vitro on human and rat hepatocytes in primary cultures and in vivo by intravenous injections in healthy rats. More than the physicochemical properties, the composition of NPs (organic, inorganic) dramatically influenced the detoxification function of the liver. Silica NPs modulated the CYP activity both in rat and human hepatocytes, in contrast to PLGA NPs. A CYP isoform-dependent effect was reported and the modulation of the metabolic hepatic activity was species-dependent. Human hepatocytes were sensitive to an exposure to PLGA NPs, whereas no marked effect was detected in rat hepatocytes. The in vitro data obtained in rat hepatocytes were correlated with the in vivo data. This study emphasizes the interest to set up relevant in vitro models using human hepatic cells to evaluate the hepatotoxicity of nanomedicines.

Verified
Journal Article
Open access
PDF file
IDImen Dakhlaoui
Imen Dakhlaoui
PBPaul J. BERNARD
Paul J. BERNARD
DPDiana Pietrzak
Diana Pietrzak
ASAlexey Simakov
Alexey Simakov
MMMaciej Maj
Maciej Maj
LILhassane Ismaili
Lhassane Ismaili
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease that has a heavy social and economic impact on all societies and for which there is still no cure. Multitarget-directed ligands (MTDLs) seem to be a promising therapeutic strategy for finding an effective treatment for this disease. For this purpose, new MTDLs were designed and synthesized in three steps by simple and cost-efficient procedures targeting calcium channel blockade, cholinesterase inhibition, and antioxidant activity. The biological and physicochemical results collected in this study allowed us the identification two sulfonamide-dihydropyridine hybrids showing simultaneous cholinesterase inhibition, calcium channel blockade, antioxidant capacity and Nrf2-ARE activating effect, that deserve to be further investigated for AD therapy.